BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Synteract, Inc. (North Carolina) Unveils New Branding at Drug Information Association 2012 to Support Enhanced Commercial Strategy


6/13/2012 9:42:23 AM

SAN DIEGO and RALEIGH-DURHAM, N.C., June 12, 2012 /PRNewswire/ -- Synteract, Inc., a full-service contract research organization (CRO), will unveil its new branding at this year's Drug Information Association (DIA) annual meeting to be held from June 24-28 in Philadelphia at the Pennsylvania Convention Center. Synteract will exhibit in booth #1925. The company has revamped its brand to better showcase the full range of Phase I-IV services and expertise it offers biotechnology, medical device, and pharmaceutical companies.

(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)

While the company's tagline Shared Work-Shared Vision has not changed, it has been enhanced by additional messaging that helps to define Synteract's updated commercial strategy and strong partnership approach. The company has evolved and expanded its service offering, scale and reach in response to client demand. The new brand platform serves to reinforce that updated perspective on Synteract to the industry. The company used images of its own people in its marketing because they are the cornerstone of the global clinical development and industry expertise supporting clients every day.

The company's continued growth on the East Coast in Research Triangle Park and in Europe has been a driver for the revamped brand identity, according to Synteract CEO Wendel Barr. "Our updated brand position reflects the evolution and growth Synteract has achieved through our commitment to serving the unique needs of emerging to midsize biotech and pharma. Our high rate of repeat business is a testament to our success, as is our support of 22 product approvals. It's the commitment of our employees that has sustained our growth as well as that of our clients. Our continued dedication to great partnerships will be more clearly communicated through this revised messaging and strong visual identity that focuses on our people they are Synteract."

As part of its strategy, the company is hiring to augment its medical, clinical, biostatistics and regulatory expertise and has increased its sales and marketing investment as well. The refocused brand identity includes a fully revamped website and tradeshow booths, increased advertising, public relations and social media efforts. Synteract's leaders are actively engaged in front of the medical, scientific and business communities through speaking engagements, contributed articles and interaction with industry associations and standards bodies such as CDISC, SCDM, DIA and others.

Barr added, "The new brand platform allows Synteract to more clearly address our differentiators within this competitive industry, giving current and prospective clients an overview of our customized approach and longstanding clinical development experience to facilitate their search for an outsourcing partner to match their specific needs. And as we move forward with European acquisition plans later this year, we want our culture to be clear."

At DIA, Synteract's growing team of drug development experts will be available to discuss the company's clinical development expertise. To set up an appointment in advance, contact Matt Smith, SVP Sales and Marketing at 760-795-2149 or msmith@synteract.com. The company will also host a reception at its booth on Monday, June 25th, 4:00 p.m.

About Synteract (www.synteract.com)
Synteract is a full-service contract research organization with a successful 17-year track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its "Shared Work Shared Vision" philosophy Synteract provides customized Phase I through IV services collaboratively and cost effectively to ensure on-time delivery of quality data so clients get to decision points faster. Headquartered in California, with offices in North Carolina and the Czech Republic, Synteract delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, cardiovascular, respiratory and ophthalmology.

CONTACT:

Rachel Hutman
Clearpoint Agency, for Synteract
rachel@clearpointagency.com
760-230-2424

SOURCE Synteract, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES